Abstract
No public abstract is available from the verified source records.
Naoki Tani, Tomonori Sato, Takeyuki Goto, Takuma Bando, Naoki Kawai, Yong Chong, Hideyuki Ikematsu
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo
10.1093/jac/dkad027 · 2023
Efficacy and safety of 5-Day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial
10.1001/jamanetworkopen.2023.54991 · 2024
A randomized phase 2/3 study of Ensitrelvir, a novel oral SARS-CoV-2 3C-Like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part
10.1128/aac.00697-22 · 2022
Durations of fever and other symptoms among COVID-19 outpatients administered ensitrelvir during the 2023 Japanese XBB epidemic period
10.1016/j.jiac.2025.102852 · 2025
Rebound of SARS-CoV-2 infection after Nirmatrelvir–ritonavir treatment
10.1056/nejmc2206449 · 2022
Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for coronavirus disease 2019 (COVID-19)
10.1093/cid/ciac512 · 2023
Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
10.1016/s1473-3099(25)00482-7 · 2026
Strain-specific anti-RBD IgG antibody titers against the WT, XBB.1.5, JN.1, and KP.3 strains consistently correlate with neutralizing activity following SARS-CoV-2 XBB.1.5-adapted mRNA vaccination
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1016/j.jiac.2025.102842 · 2025
Distinct features of SARS-CoV-2 humoral immunity against omicron breakthrough infection
10.1016/j.vaccine.2023.10.035 · 2023
Use of coefficient of variation in assessing variability of quantitative assays
2002
Clinical, virologic, and immunologic evaluation of symptomatic coronavirus disease 2019 rebound following Nirmatrelvir/Ritonavir treatment
10.1093/cid/ciac663 · 2023
Association of Nirmatrelvir/Ritonavir treatment and COVID-19-Neutralizing antibody titers in a longitudinal health care worker cohort
10.1093/ofid/ofad625 · 2024
Does Nirmatrelvir/Ritonavir influence the immune response against SARS-CoV-2, independently from rebound?
10.3390/microorganisms11102607 · 2023
T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses
10.1038/s41467-021-21856-3 · 2021
SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase
10.1016/j.immuni.2024.01.017 · 2024
Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19
10.1056/nejmoa2118542 · 2022
No additional external references are available.